Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F20%3A00533049" target="_blank" >RIV/67985823:_____/20:00533049 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.liebertpub.com/doi/10.1089/ars.2020.8024" target="_blank" >https://www.liebertpub.com/doi/10.1089/ars.2020.8024</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1089/ars.2020.8024" target="_blank" >10.1089/ars.2020.8024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism

Popis výsledku v původním jazyce

Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent.nCritical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system.nFuture Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.n

Název v anglickém jazyce

Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism

Popis výsledku anglicky

Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent.nCritical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system.nFuture Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.n

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/NV19-01-00101" target="_blank" >NV19-01-00101: Nádor pankreatu: metabolické změny asociované s inzulínovou rezistencí</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Antioxidants & Redox Signaling

ISSN

1523-0864

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

32

Strana od-do

966-997

Kód UT WoS článku

000525301800001

EID výsledku v databázi Scopus

2-s2.0-85086841484